Twist Bioscience (TWST) Financials

$34.11 +2.28 (+7.16%)

Closing price 10/24/2025 04:00 PM Eastern

Extended Trading

$34.42 +0.31 (+0.91%)

As of 10/24/2025 07:54 PM Eastern

Annual Income Statements for Twist Bioscience

This table shows Twist Bioscience's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	9/30/2017	9/30/2018	9/30/2019	9/30/2020	9/30/2021	9/30/2022	9/30/2023	9/30/2024
Net Income / (Loss) Attributable to Common Shareholders	-59	-71	-108	-140	-152	-218	-205	-209
Consolidated Net Income / (Loss)	-59	-71	-108	-140	-152	-218	-205	-209
Net Income / (Loss) Continuing Operations	-59	-71	-108	-140	-152	-218	-205	-209
Total Pre-Tax Income	-59	-71	-107	-140	-154	-228	-203	-208
Total Operating Income	-58	-71	-109	-140	-153	-235	-217	-221
Total Gross Profit	-13	-6.76	6.96	29	52	84	90	133
Total Revenue	11	25	54	90	132	204	245	313
Operating Revenue	11	25	54	90	132	204	245	313
Total Cost of Revenue	24	32	47	61	81	119	155	180
Operating Cost of Revenue	24	32	47	61	81	119	155	180
Total Operating Expenses	45	64	116	169	204	319	307	354
Selling, General & Admin Expense	26	43	80	103	136	213	190	218
Research & Development Expense	19	20	36	43	69	120	107	91
Other Operating Expenses / (Income)	-	-	0.00	0.00	-0.53	-14	-5.91	0.00
Impairment Charge	-	-	-	-	-	0.00	6.79	45
Restructuring Charge	-	-	-	-	0.00	0.00	9.38	0.00
Total Other Income / (Expense), net	-0.55	-0.44	1.47	0.53	-1.30	6.50	14	13
Interest Expense	0.91	1.31	1.29	0.79	0.37	0.08	0.01	0.03
Interest & Investment Income	0.41	1.00	3.03	1.50	0.44	7.67	14	15
Other Income / (Expense), net	-0.06	-0.12	-0.27	-0.18	-1.37	-1.09	-0.67	-2.65
Income Tax Expense	0.28	0.24	0.29	0.38	-1.93	-10	1.15	0.56
Basic Earnings per Share	($24.49)	($25.51)	($3.92)	($3.57)	($3.15)	($4.04)	($3.60)	($3.60)
Weighted Average Basic Shares Outstanding	2.42M	2.79M	27.46M	39.19M	48.25M	53.89M	56.89M	58.02M
Diluted Earnings per Share	($24.49)	($25.51)	($3.92)	($3.57)	($3.15)	($4.04)	($3.60)	($3.60)
Weighted Average Diluted Shares Outstanding	2.42M	2.79M	27.46M	39.19M	48.25M	53.89M	56.89M	58.02M
Weighted Average Basic & Diluted Shares Outstanding	2.42M	2.79M	27.46M	39.19M	48.25M	56.57M	57.67M	59.36M

This table shows Twist Bioscience's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-51	-42	-59	-57	-46	-43	-45	-86	-35	-32	-39
Consolidated Net Income / (Loss)	-51	-42	-59	-57	-46	-43	-45	-86	-35	-32	-39
Net Income / (Loss) Continuing Operations	-51	-42	-59	-57	-46	-43	-45	-86	-35	-32	-39
Total Pre-Tax Income	-51	-42	-58	-57	-46	-43	-45	-85	-35	-31	-39
Total Operating Income	-57	-45	-62	-61	-50	-47	-49	-89	-36	-35	-42
Total Gross Profit	26	25	19	22	25	29	31	35	38	43	46
Total Revenue	57	54	60	64	67	71	75	81	85	89	93
Operating Revenue	57	54	60	64	67	71	75	81	85	89	93
Total Cost of Revenue	32	29	42	42	42	43	44	46	46	46	47
Operating Cost of Revenue	32	29	42	42	42	43	44	46	46	46	47
Total Operating Expenses	83	69	80	83	75	76	80	124	74	77	88
Selling, General & Admin Expense	54	42	54	46	47	53	56	57	53	56	64
Research & Development Expense	30	31	27	25	24	23	24	22	21	21	24
Total Other Income / (Expense), net	6.05	2.88	3.16	4.01	3.65	4.09	3.74	3.54	1.29	3.15	2.41
Interest Expense	0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.02	0.14
Interest & Investment Income	6.53	3.04	3.46	3.97	3.89	4.12	3.94	3.66	3.62	3.24	2.80
Other Income / (Expense), net	-0.46	-0.16	-0.31	0.04	-0.25	-0.03	-0.20	-0.12	-2.30	-0.07	-0.25
Income Tax Expense	0.29	0.08	0.68	0.62	-0.22	0.12	0.35	0.19	-0.10	0.10	0.18
Basic Earnings per Share	($0.92)	($0.74)	($1.04)	($1.01)	($0.81)	($0.75)	($0.79)	($1.47)	($0.59)	($0.53)	($0.66)
Weighted Average Basic Shares Outstanding	53.89M	56.44M	56.78M	57.04M	56.89M	57.50M	57.78M	58.15M	58.02M	59.16M	59.65M
Diluted Earnings per Share	($0.92)	($0.74)	($1.04)	($1.01)	($0.81)	($0.75)	($0.79)	($1.47)	($0.59)	($0.53)	($0.66)
Weighted Average Diluted Shares Outstanding	53.89M	56.44M	56.78M	57.04M	56.89M	57.50M	57.78M	58.15M	58.02M	59.16M	59.65M
Weighted Average Basic & Diluted Shares Outstanding	56.57M	56.86M	57.15M	57.40M	57.67M	57.82M	58.23M	58.59M	59.36M	59.65M	59.92M

This table details how cash moves in and out of Twist Bioscience's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	9/30/2017	9/30/2018	9/30/2019	9/30/2020	9/30/2021	9/30/2022	9/30/2023	9/30/2024
Net Change in Cash & Equivalents	2.51	50	-34	47	373	-87	-91	-60
Net Cash From Operating Activities	-51	-66	-88	-142	-112	-124	-142	-64
Net Cash From Continuing Operating Activities	-51	-66	-88	-142	-113	-124	-143	-64
Net Income / (Loss) Continuing Operations	-59	-71	-108	-140	-152	-218	-205	-209
Consolidated Net Income / (Loss)	-59	-71	-108	-140	-152	-218	-205	-209
Depreciation Expense	5.02	5.73	6.11	6.68	9.75	17	29	31
Non-Cash Adjustments To Reconcile Net Income	3.02	3.26	12	16	39	97	40	98
Changes in Operating Assets and Liabilities, net	-0.13	-4.22	3.00	-25	-9.38	-20	-1.01	15
Net Cash From Investing Activities	-9.99	27	-105	-115	156	-233	51	-3.07
Net Cash From Continuing Investing Activities	-9.99	27	-105	-115	156	-233	51	-3.07
Purchase of Property, Plant & Equipment	-6.59	-3.69	-15	-9.87	-27	-102	-28	-5.08
Acquisitions	-	-	0.00	0.00	-0.48	-14	0.00	0.00
Purchase of Investments	-41	-3.52	-178	-203	-59	-218	-76	-52
Sale and/or Maturity of Investments	37	35	88	98	242	100	155	54
Net Cash From Financing Activities	64	89	159	304	329	271	0.91	6.89
Net Cash From Continuing Financing Activities	64	89	159	304	329	271	0.91	6.89
Repayment of Debt	-4.17	0.00	-2.50	-3.33	-3.33	-1.56	0.00	0.00
Repurchase of Common Equity	0.00	-2.36	0.00	-2.42	-11	-7.75	-4.41	-3.98
Issuance of Common Equity	0.21	0.33	158	306	338	280	1.38	11
Effect of Exchange Rate Changes	-	-	0.03	0.02	0.02	-0.32	-0.03	0.13
Cash Interest Paid	0.70	0.75	0.78	0.44	0.17	0.01	0.00	0.00
Cash Income Taxes Paid	0.01	0.18	0.29	0.17	0.10	0.25	0.42	0.34

This table details how cash moves in and out of Twist Bioscience's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	2.44	-61	-1.53	-5.72	-23	-20	-23	-4.18	-13	-5.07	-11
Net Cash From Operating Activities	-1.27	-54	-44	-23	-21	-23	-19	-6.38	-15	-21	-13
Net Cash From Continuing Operating Activities	-0.28	-54	-44	-23	-21	-23	-19	-6.38	-15	-21	-13
Net Income / (Loss) Continuing Operations	-51	-42	-59	-57	-46	-43	-45	-86	-35	-32	-39
Consolidated Net Income / (Loss)	-51	-42	-59	-57	-46	-43	-45	-86	-35	-32	-39
Depreciation Expense	4.95	5.29	7.03	8.49	8.50	8.17	8.30	8.30	6.66	6.38	6.40
Non-Cash Adjustments To Reconcile Net Income	33	-5.92	9.69	13	22	11	14	58	14	12	21
Changes in Operating Assets and Liabilities, net	-0.54	-12	-1.85	12	0.44	0.53	3.46	13	-1.14	-8.19	-1.22
Net Cash From Investing Activities	2.78	-6.97	41	19	-2.25	4.17	-5.24	-0.71	-1.29	-1.54	-1.43
Net Cash From Continuing Investing Activities	2.78	-6.97	41	19	-2.25	4.17	-5.24	-0.71	-1.29	-1.54	-1.43
Purchase of Property, Plant & Equipment	-16	-12	-9.05	-4.51	-2.39	-1.51	-0.60	-0.97	-2.00	-2.27	-4.14
Purchase of Investments	-	-23	-28	-7.82	-18	-18	-11	-1.75	-21	-21	-4.93
Sale and/or Maturity of Investments	25	28	78	31	18	24	6.00	2.00	22	21	7.65
Net Cash From Financing Activities	1.24	-0.40	1.53	-0.66	0.44	-1.47	1.83	2.91	3.63	18	3.20
Net Cash From Continuing Financing Activities	1.24	-0.40	1.53	-0.66	0.44	-1.47	1.83	2.91	3.63	18	3.20
Repurchase of Common Equity	-1.62	-1.00	-1.26	-1.01	-1.13	-2.42	-1.54	-0.01	-0.01	-0.01	-0.01
Issuance of Common Equity	5.26	0.60	0.25	0.35	0.17	0.95	1.32	2.92	5.68	2.95	0.77
Effect of Exchange Rate Changes	-0.32	0.27	0.07	-0.32	-0.05	0.12	-0.07	0.00	0.07	-0.05	0.10
Cash Income Taxes Paid	0.12	0.05	0.09	0.10	0.18	0.04	0.30	0.02	-0.02	0.00	0.01

This table presents Twist Bioscience's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024
Period end date	9/30/2018	9/30/2019	9/30/2020	9/30/2021	9/30/2022	9/30/2023	9/30/2024
Total Assets	116	187	399	702	961	776	614
Total Current Assets	96	160	335	546	596	424	347
Cash & Equivalents	81	47	94	466	379	286	226
Short-Term Investments	0.00	91	196	12	126	50	50
Accounts Receivable	5.42	12	26	29	40	44	35
Inventories, net	6.03	7.33	12	32	39	32	24
Prepaid Expenses	3.47	2.59	6.20	8.28	12	12	11
Plant, Property, & Equipment, net	12	21	25	44	139	132	103
Total Noncurrent Assets	7.79	6.02	39	111	225	220	165
Goodwill	1.14	1.14	1.14	22	86	86	86
Intangible Assets	0.71	0.51	0.31	18	60	54	14
Other Noncurrent Operating Assets	5.94	4.38	37	71	80	80	65
Total Liabilities & Shareholders' Equity	116	187	399	702	961	776	614
Total Liabilities	27	35	63	121	172	153	142
Total Current Liabilities	19	30	36	63	91	73	71
Accounts Payable	7.53	9.76	4.83	15	20	14	1.63
Accrued Expenses	2.17	5.97	3.90	6.44	10	11	15
Current Employee Benefit Liabilities	5.40	10	15	22	27	26	34
Other Current Liabilities	0.94	0.82	9.02	18	33	23	21
Total Noncurrent Liabilities	8.19	4.56	27	58	81	80	71
Noncurrent Deferred Revenue	-	-	-	-	-	-	0.00
Other Noncurrent Operating Liabilities	0.98	0.16	25	58	81	80	71
Commitments & Contingencies	0.00	0.00	-	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-201	152	336	581	789	623	473
Total Preferred & Common Equity	-201	152	336	581	789	623	473
Total Common Equity	-201	152	336	581	789	623	473
Common Stock	9.35	470	795	1,191	1,620	1,657	1,715
Retained Earnings	-211	-319	-458	-611	-828	-1,033	-1,242
Accumulated Other Comprehensive Income / (Loss)	0.09	0.18	0.09	0.55	-1.84	-0.76	-0.52

This table presents Twist Bioscience's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025
Period end date	6/30/2022	12/31/2022	3/31/2023	6/30/2023	12/31/2023	3/31/2024	6/30/2024	12/31/2024	3/31/2025
Total Assets	980	910	854	810	733	703	638	609	596
Total Current Assets	624	542	489	446	390	372	362	345	338
Cash & Equivalents	376	317	315	307	266	243	239	221	210
Short-Term Investments	151	122	72	50	45	50	50	49	47
Accounts Receivable	41	44	48	43	35	36	32	39	50
Inventories, net	43	45	40	36	31	30	28	24	21
Prepaid Expenses	12	14	14	9.46	13	12	12	12	10
Plant, Property, & Equipment, net	127	145	147	141	126	121	106	101	97
Total Noncurrent Assets	229	223	218	224	216	210	170	163	160
Goodwill	86	86	86	86	86	86	86	86	86
Intangible Assets	61	58	57	56	53	52	15	14	14
Other Noncurrent Operating Assets	82	79	75	82	77	72	69	63	60
Total Liabilities & Shareholders' Equity	980	910	854	810	733	703	638	609	596
Total Liabilities	159	164	150	153	143	143	147	153	156
Total Current Liabilities	93	84	72	73	65	67	74	70	75
Accounts Payable	21	20	13	12	9.26	7.70	6.63	7.50	8.06
Accrued Expenses	9.50	10	11	10	14	15	15	20	20
Current Employee Benefit Liabilities	28	23	24	27	21	25	32	22	25
Other Current Liabilities	34	30	23	23	21	20	21	20	22
Total Noncurrent Liabilities	66	80	78	80	78	75	73	83	81
Noncurrent Deferred Revenue	-	-	-	-	-	-	-	15	15
Other Noncurrent Operating Liabilities	66	80	78	80	78	75	73	68	66
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	821	746	704	658	590	560	491	456	440
Total Preferred & Common Equity	821	746	704	658	590	560	491	456	440
Total Common Equity	821	746	704	658	590	560	491	456	440
Common Stock	1,599	1,617	1,633	1,645	1,667	1,682	1,699	1,730	1,754
Retained Earnings	-777	-870	-929	-987	-1,076	-1,122	-1,207	-1,274	-1,313
Accumulated Other Comprehensive Income / (Loss)	-1.38	-0.61	0.11	-0.64	-0.57	-0.66	-0.74	-0.65	-0.66

This table displays calculated financial ratios and metrics derived from Twist Bioscience's official financial filings.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	9/30/2017	9/30/2018	9/30/2019	9/30/2020	9/30/2021	9/30/2022	9/30/2023	9/30/2024
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	136.16%	113.89%	65.67%	46.87%	53.83%	20.41%	27.69%
EBITDA Growth	0.00%	-21.01%	-60.83%	-28.51%	-8.43%	-51.40%	11.36%	1.22%
EBIT Growth	0.00%	-20.74%	-54.38%	-28.54%	-9.86%	-53.06%	7.65%	-2.60%
NOPAT Growth	0.00%	-20.65%	-54.27%	-28.69%	-9.03%	-53.72%	7.50%	-1.69%
Net Income Growth	0.00%	-20.11%	-51.14%	-29.96%	-8.70%	-43.24%	6.08%	-2.01%
EPS Growth	0.00%	-4.17%	84.63%	8.93%	11.76%	-28.25%	10.89%	0.00%
Operating Cash Flow Growth	0.00%	-28.97%	-32.91%	-61.77%	21.10%	-10.82%	-14.54%	55.01%
Free Cash Flow Firm Growth	0.00%	0.00%	-18.49%	-59.42%	-25.98%	-114.59%	55.09%	58.70%
Invested Capital Growth	0.00%	0.00%	20.45%	134.92%	104.94%	172.14%	0.91%	-31.61%
Revenue Q/Q Growth	0.00%	0.00%	15.58%	22.75%	4.35%	10.51%	4.09%	6.02%
EBITDA Q/Q Growth	0.00%	0.00%	-13.00%	5.80%	-13.66%	0.08%	2.32%	5.03%
EBIT Q/Q Growth	0.00%	0.00%	-12.15%	5.11%	-12.28%	-7.50%	3.10%	5.10%
NOPAT Q/Q Growth	0.00%	0.00%	-12.23%	5.15%	-11.57%	-7.84%	3.02%	5.99%
Net Income Q/Q Growth	0.00%	0.00%	-11.82%	4.68%	-12.52%	-4.75%	2.33%	5.26%
EPS Q/Q Growth	0.00%	0.00%	59.25%	12.93%	-17.54%	-2.28%	2.97%	5.76%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-8.20%	-1.31%	-9.35%	21.24%	-15.80%	7.75%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-3.20%	-9.48%	2.22%	5.76%	2.88%
Invested Capital Q/Q Growth	0.00%	0.00%	-4.24%	19.46%	11.89%	-2.96%	-4.46%	-2.69%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	-123.09%	-26.59%	12.80%	31.85%	39.08%	41.38%	36.61%	42.61%
EBITDA Margin	-496.15%	-254.24%	-191.18%	-148.30%	-109.48%	-107.75%	-79.32%	-61.36%
Operating Margin	-543.16%	-277.50%	-200.15%	-155.47%	-115.41%	-115.33%	-88.60%	-70.56%
EBIT Margin	-543.67%	-277.97%	-200.63%	-155.67%	-116.45%	-115.87%	-88.87%	-71.41%
Profit (Net Income) Margin	-550.85%	-280.16%	-197.98%	-155.31%	-114.94%	-107.02%	-83.48%	-66.69%
Tax Burden Percent	100.47%	100.34%	100.27%	100.27%	98.75%	95.44%	100.57%	100.27%
Interest Burden Percent	100.84%	100.44%	98.41%	99.49%	99.96%	96.78%	93.41%	93.15%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-548.12%	-383.56%	-269.74%	-137.50%	-84.51%	-53.20%	-63.97%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-486.62%	-352.31%	-249.59%	-125.63%	-73.60%	-40.70%	-46.30%
Return on Net Nonoperating Assets (RNNOA)	0.00%	388.15%	294.27%	212.43%	104.33%	52.71%	24.24%	25.88%
Return on Equity (ROE)	0.00%	-159.97%	-89.30%	-57.31%	-33.17%	-31.80%	-28.97%	-38.08%
Cash Return on Invested Capital (CROIC)	0.00%	-748.12%	-402.12%	-350.31%	-206.32%	-177.03%	-54.11%	-26.42%
Operating Return on Assets (OROA)	0.00%	-61.04%	-72.07%	-47.88%	-27.99%	-28.36%	-25.07%	-32.14%
Return on Assets (ROA)	0.00%	-61.52%	-71.12%	-47.77%	-27.63%	-26.19%	-23.55%	-30.02%
Return on Common Equity (ROCE)	0.00%	361.79%	18.27%	-57.31%	-33.17%	-31.80%	-28.97%	-38.08%
Return on Equity Simple (ROE_SIMPLE)	0.00%	35.37%	-70.80%	-41.61%	-26.19%	-27.60%	-32.82%	-44.16%
Net Operating Profit after Tax (NOPAT)	-41	-49	-76	-98	-107	-164	-152	-155
NOPAT Margin	-380.21%	-194.25%	-140.10%	-108.83%	-80.79%	-80.73%	-62.02%	-49.39%
Net Nonoperating Expense Percent (NNEP)	0.00%	-61.50%	-31.25%	-20.15%	-11.87%	-10.91%	-12.50%	-17.67%
Cost of Revenue to Revenue	223.09%	126.59%	87.20%	68.15%	60.92%	58.62%	63.39%	57.39%
SG&A Expenses to Revenue	242.04%	170.88%	147.33%	114.61%	102.70%	104.61%	77.41%	69.78%
R&D to Revenue	178.03%	80.02%	65.61%	47.73%	52.20%	59.10%	43.61%	29.03%
Operating Expenses to Revenue	420.07%	250.90%	212.94%	187.32%	154.49%	156.71%	125.20%	113.17%
Earnings before Interest and Taxes (EBIT)	-59	-71	-109	-140	-154	-236	-218	-223
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-53	-65	-104	-134	-145	-219	-194	-192
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	5.11	10.09	9.08	2.52	1.87	5.60
Price to Tangible Book Value (P/TBV)	0.00	0.00	5.17	10.13	9.76	3.09	2.41	7.11
Price to Revenue (P/Rev)	6.50	2.75	14.30	37.66	39.84	9.76	4.74	8.46
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	16.06	29.81	60.94	45.89	5.21	2.88	12.08
Enterprise Value to Revenue (EV/Rev)	0.00	11.38	11.90	34.49	36.25	7.28	3.37	7.57
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.11	0.05	0.01	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.08	0.03	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-0.80	-0.84	-0.85	-0.83	-0.72	-0.60	-0.56
Leverage Ratio	0.00	1.30	1.26	1.20	1.20	1.21	1.23	1.27
Compound Leverage Factor	0.00	1.31	1.24	1.19	1.20	1.18	1.15	1.18
Debt to Total Capital	0.00%	9.84%	4.84%	1.39%	0.27%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	2.53%	2.09%	0.98%	0.27%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	7.31%	2.75%	0.41%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	294.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-203.91%	95.16%	98.61%	99.73%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	-0.15	-0.07	-0.04	-0.01	0.00	0.00	0.00
Net Debt to EBITDA	0.00	1.10	1.25	2.14	3.29	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	-0.11	-0.04	-0.01	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	-0.20	-0.10	-0.05	-0.01	0.00	0.00	0.00
Net Debt to NOPAT	0.00	1.44	1.71	2.91	4.46	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	-0.15	-0.06	-0.01	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	-1.97	10.18	30.87	25.16	5.76	2.63	8.23
Noncontrolling Interest Sharing Ratio	0.00%	326.16%	120.46%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	0.00	5.16	5.28	9.29	8.67	6.58	5.79	4.88
Quick Ratio	0.00	4.65	4.95	8.78	8.03	6.01	5.19	4.38
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-67	-80	-127	-160	-344	-155	-64
Operating Cash Flow to CapEx	-810.70%	-1,802.34%	-596.75%	-1,441.58%	-414.78%	-122.12%	-512.88%	-1,262.69%
Free Cash Flow to Firm to Interest Expense	0.00	-51.34	-61.73	-161.81	-437.12	-4,303.13	-30,922.66	-2,201.82
Operating Cash Flow to Interest Expense	-56.69	-50.39	-67.96	-180.76	-305.84	-1,554.81	-28,494.80	-2,210.14
Operating Cash Flow Less CapEx to Interest Expense	-63.68	-53.19	-79.35	-193.29	-379.58	-2,828.03	-34,050.60	-2,385.17
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.22	0.36	0.31	0.24	0.24	0.28	0.45
Accounts Receivable Turnover	0.00	4.69	6.21	4.68	4.82	5.91	5.81	7.93
Inventory Turnover	0.00	5.34	7.10	6.26	3.66	3.36	4.35	6.40
Fixed Asset Turnover	0.00	2.06	3.28	3.89	3.80	2.22	1.81	2.67
Accounts Payable Turnover	0.00	4.27	5.49	8.42	8.17	6.82	9.10	22.91
Days Sales Outstanding (DSO)	0.00	77.79	58.80	77.94	75.75	61.72	62.81	46.05
Days Inventory Outstanding (DIO)	0.00	68.35	51.40	58.31	99.80	108.75	83.83	57.04
Days Payable Outstanding (DPO)	0.00	85.40	66.54	43.36	44.66	53.52	40.10	15.93
Cash Conversion Cycle (CCC)	0.00	60.75	43.67	92.89	130.89	116.95	106.53	87.15
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	0.00	18	22	51	105	284	287	196
Invested Capital Turnover	0.00	2.82	2.74	2.48	1.70	1.05	0.86	1.30
Increase / (Decrease) in Invested Capital	0.00	18	3.69	29	54	180	2.60	-91
Enterprise Value (EV)	0.00	289	647	3,108	4,796	1,481	826	2,371
Market Capitalization	70	70	778	3,393	5,273	1,986	1,163	2,647
Book Value per Share	$0.00	($72.12)	$4.67	$7.53	$11.78	$14.01	$10.86	$8.07
Tangible Book Value per Share	$0.00	($72.78)	$4.62	$7.50	$10.96	$11.42	$8.42	$6.36
Total Capital	0.00	99	160	341	582	789	623	473
Total Debt	0.00	9.72	7.73	4.74	1.55	0.00	0.00	0.00
Total Long-Term Debt	0.00	7.22	4.40	1.40	0.00	0.00	0.00	0.00
Net Debt	0.00	-71	-130	-285	-476	-505	-336	-276
Capital Expenditures (CapEx)	6.33	3.67	15	9.87	27	102	28	5.08
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-1.12	-4.99	12	7.13	0.85	15	-0.63
Debt-free Net Working Capital (DFNWC)	0.00	80	133	302	485	506	351	276
Net Working Capital (NWC)	0.00	77	130	299	483	506	351	276
Net Nonoperating Expense (NNE)	18	22	31	42	45	54	53	54
Net Nonoperating Obligations (NNO)	0.00	-71	-130	-285	-476	-505	-336	-276
Total Depreciation and Amortization (D&A)	5.12	6.04	5.14	6.65	9.22	17	23	31
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-4.42%	-9.18%	13.51%	5.39%	0.42%	5.92%	-0.20%
Debt-free Net Working Capital to Revenue	0.00%	313.19%	244.76%	335.38%	366.50%	248.48%	143.17%	88.11%
Net Working Capital to Revenue	0.00%	303.35%	238.63%	331.68%	365.32%	248.48%	143.17%	88.11%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($3.92)	($3.57)	($3.15)	$0.00	($3.60)	($3.60)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	33.12M	45.15M	49.63M	0.00	56.89M	58.02M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($3.92)	($3.57)	($3.15)	$0.00	($3.60)	($3.60)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	33.12M	45.15M	49.63M	0.00	56.89M	58.02M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($3.92)	($3.57)	($3.15)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	27.46M	39.19M	48.25M	0.00	57.67M	59.36M
Normalized Net Operating Profit after Tax (NOPAT)	-41	-49	-76	-82	-107	-164	-141	-123
Normalized NOPAT Margin	-380.21%	-194.25%	-140.10%	-91.35%	-80.79%	-80.73%	-57.40%	-39.34%
Pre Tax Income Margin	-548.25%	-279.21%	-197.44%	-154.88%	-116.39%	-112.14%	-83.01%	-66.51%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-64.68	-53.83	-84.32	-178.22	-419.88	-2,948.29	-43,565.20	-7,706.24
NOPAT to Interest Expense	-45.23	-37.62	-58.88	-124.59	-291.30	-2,054.29	-30,402.26	-5,330.40
EBIT Less CapEx to Interest Expense	-71.67	-56.63	-95.71	-190.76	-493.62	-4,221.50	-49,121.00	-7,881.28
NOPAT Less CapEx to Interest Expense	-52.23	-40.41	-70.27	-137.13	-365.04	-3,327.50	-35,958.06	-5,505.44
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-3.31%	0.00%	-1.73%	-7.13%	-3.56%	-2.15%	-1.90%

This table displays calculated financial ratios and metrics derived from Twist Bioscience's official financial filings.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	51.01%	29.09%	25.04%	13.59%	16.82%	31.81%	25.13%	27.81%	26.53%	24.08%	23.23%
EBITDA Growth	-32.67%	25.41%	3.79%	8.24%	20.09%	1.67%	25.73%	-54.53%	24.30%	27.05%	13.18%
EBIT Growth	-40.26%	20.16%	-1.47%	1.06%	12.17%	-4.96%	20.75%	-46.60%	23.86%	26.16%	14.82%
NOPAT Growth	-42.85%	20.22%	-1.37%	0.62%	11.89%	-5.26%	20.68%	-46.30%	28.07%	26.25%	14.99%
Net Income Growth	-23.94%	8.21%	2.49%	5.16%	9.53%	-2.83%	23.10%	-49.09%	25.06%	26.54%	13.55%
EPS Growth	-10.84%	18.68%	7.96%	6.48%	11.96%	-1.35%	24.04%	-45.54%	27.16%	29.33%	16.46%
Operating Cash Flow Growth	96.36%	-15.90%	-4.60%	31.39%	-1,534.10%	57.51%	56.14%	72.76%	26.00%	6.73%	33.14%
Free Cash Flow Firm Growth	-169.98%	39.91%	58.09%	79.44%	82.85%	96.57%	115.19%	173.07%	273.83%	1,768.70%	258.63%
Invested Capital Growth	172.14%	41.45%	22.15%	2.50%	0.91%	-9.34%	-15.65%	-32.85%	-31.61%	-33.63%	-31.42%
Revenue Q/Q Growth	2.13%	-5.35%	10.95%	5.92%	5.03%	6.80%	5.32%	8.18%	3.98%	4.73%	4.60%
EBITDA Q/Q Growth	8.01%	24.60%	-39.04%	4.85%	19.89%	7.22%	-5.01%	-97.97%	60.76%	10.58%	-24.97%
EBIT Q/Q Growth	6.61%	21.88%	-38.30%	1.94%	17.09%	6.65%	-4.42%	-81.39%	56.94%	9.46%	-20.45%
NOPAT Q/Q Growth	7.02%	21.52%	-38.11%	1.39%	17.55%	6.25%	-4.07%	-81.89%	59.47%	3.88%	-19.96%
Net Income Q/Q Growth	15.54%	18.18%	-41.44%	2.98%	19.43%	7.00%	-5.78%	-88.10%	59.50%	8.83%	-24.48%
EPS Q/Q Growth	14.81%	19.57%	-40.54%	2.88%	19.80%	7.41%	-5.33%	-86.08%	59.86%	10.17%	-24.53%
Operating Cash Flow Q/Q Growth	96.29%	-4,167.56%	18.09%	47.14%	11.57%	-10.96%	15.45%	67.16%	-140.20%	-39.87%	39.40%
Free Cash Flow Firm Q/Q Growth	9.39%	44.76%	17.20%	50.38%	24.44%	88.94%	466.28%	138.74%	79.75%	6.16%	-21.28%
Invested Capital Q/Q Growth	-2.96%	8.16%	2.81%	-5.02%	-4.46%	-2.83%	-4.34%	-24.39%	-2.69%	-5.69%	-1.16%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	44.88%	45.72%	30.76%	34.35%	36.63%	40.51%	41.01%	43.30%	45.14%	48.29%	49.60%
EBITDA Margin	-91.40%	-72.81%	-91.25%	-81.97%	-62.52%	-54.32%	-54.16%	-99.11%	-37.41%	-31.94%	-38.16%
Operating Margin	-99.24%	-82.28%	-102.42%	-95.36%	-74.85%	-65.70%	-64.92%	-109.16%	-42.55%	-39.05%	-44.79%
EBIT Margin	-100.04%	-82.57%	-102.93%	-95.29%	-75.22%	-65.75%	-65.19%	-109.30%	-45.26%	-39.13%	-45.06%
Profit (Net Income) Margin	-89.20%	-77.10%	-98.30%	-90.05%	-69.08%	-60.15%	-60.41%	-105.04%	-40.91%	-35.61%	-42.38%
Tax Burden Percent	100.57%	100.18%	101.16%	101.10%	99.52%	100.28%	100.76%	100.22%	99.72%	100.31%	100.45%
Interest Burden Percent	88.65%	93.21%	94.41%	93.47%	92.27%	91.24%	91.97%	95.89%	90.63%	90.74%	93.64%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-72.72%	-47.34%	-56.80%	-52.97%	-44.95%	-41.15%	-43.26%	-89.84%	-38.57%	-38.90%	-48.47%
ROIC Less NNEP Spread (ROIC-NNEP)	-70.41%	-44.84%	-53.57%	-49.61%	-42.30%	-38.45%	-39.95%	-82.63%	-35.50%	-36.38%	-44.75%
Return on Net Nonoperating Assets (RNNOA)	50.43%	27.69%	33.91%	29.69%	25.19%	21.57%	21.52%	46.51%	19.85%	20.24%	24.63%
Return on Equity (ROE)	-22.29%	-19.65%	-22.89%	-23.27%	-19.76%	-19.57%	-21.74%	-43.33%	-18.73%	-18.66%	-23.84%
Cash Return on Invested Capital (CROIC)	-177.03%	-93.91%	-74.54%	-55.29%	-54.11%	-42.60%	-32.67%	-26.19%	-26.42%	-22.48%	-25.34%
Operating Return on Assets (OROA)	-24.49%	-21.01%	-25.01%	-25.07%	-21.22%	-21.00%	-23.24%	-44.55%	-20.37%	-19.26%	-24.13%
Return on Assets (ROA)	-21.83%	-19.62%	-23.88%	-23.69%	-19.49%	-19.21%	-21.54%	-42.82%	-18.41%	-17.53%	-22.70%
Return on Common Equity (ROCE)	-22.29%	-19.65%	-22.89%	-23.27%	-19.76%	-19.57%	-21.74%	-43.33%	-18.73%	-18.66%	-23.84%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-28.69%	-30.20%	-31.86%	0.00%	-34.88%	-34.30%	-44.86%	0.00%	-43.28%	-43.43%
Net Operating Profit after Tax (NOPAT)	-40	-31	-43	-43	-35	-33	-34	-62	-25	-24	-29
NOPAT Margin	-69.47%	-57.59%	-71.69%	-66.75%	-52.40%	-45.99%	-45.45%	-76.41%	-29.78%	-27.34%	-31.35%
Net Nonoperating Expense Percent (NNEP)	-2.30%	-2.50%	-3.23%	-3.36%	-2.65%	-2.70%	-3.31%	-7.22%	-3.08%	-2.52%	-3.72%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-5.57%	-	-	-	-5.32%	-6.61%
Cost of Revenue to Revenue	55.12%	54.28%	69.24%	65.65%	63.37%	59.49%	58.99%	56.70%	54.86%	51.71%	50.40%
SG&A Expenses to Revenue	94.51%	78.03%	89.67%	72.26%	70.79%	73.90%	73.87%	69.72%	62.73%	63.32%	68.62%
R&D to Revenue	51.66%	57.60%	45.50%	38.48%	35.47%	32.31%	32.07%	27.58%	24.95%	24.02%	25.77%
Operating Expenses to Revenue	144.12%	128.00%	133.18%	129.71%	111.48%	106.21%	105.93%	152.45%	87.68%	87.34%	94.39%
Earnings before Interest and Taxes (EBIT)	-57	-45	-62	-61	-50	-47	-49	-89	-38	-35	-42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-52	-39	-55	-52	-42	-39	-41	-81	-32	-28	-35
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.52	1.80	1.22	1.76	1.87	3.59	3.54	5.84	5.60	6.05	5.32
Price to Tangible Book Value (P/TBV)	3.09	2.24	1.53	2.24	2.41	4.69	4.70	7.35	7.11	7.75	6.88
Price to Revenue (P/Rev)	9.76	6.24	3.76	4.92	4.74	8.06	7.15	9.72	8.46	8.35	6.74
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	5.21	2.95	1.49	2.66	2.88	6.47	6.34	12.79	12.08	13.44	11.39
Enterprise Value to Revenue (EV/Rev)	7.28	4.21	2.06	3.40	3.37	6.88	6.09	8.74	7.57	7.53	6.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.72	-0.62	-0.63	-0.60	-0.60	-0.56	-0.54	-0.56	-0.56	-0.56	-0.55
Leverage Ratio	1.21	1.24	1.20	1.21	1.23	1.23	1.23	1.26	1.27	1.28	1.30
Compound Leverage Factor	1.08	1.15	1.13	1.13	1.13	1.12	1.13	1.21	1.15	1.16	1.22
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	6.37	4.28	2.52	3.44	3.34	7.51	6.79	9.61	9.23	8.81	6.83
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.58	6.46	6.79	6.12	5.79	5.98	5.51	4.91	4.88	4.96	4.51
Quick Ratio	6.01	5.76	6.04	5.49	5.19	5.31	4.88	4.36	4.38	4.45	4.10
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-220	-121	-101	-50	-38	-4.17	15	36	65	70	55
Operating Cash Flow to CapEx	-7.70%	-457.29%	-489.21%	-519.23%	-865.19%	-1,525.43%	-3,221.06%	-660.93%	-765.23%	-944.80%	-313.37%
Free Cash Flow to Firm to Interest Expense	-8,788.67	-121,380.00	-50,251.95	-49,865.70	-37,679.70	0.00	0.00	0.00	2,258.58	2,897.22	382.77
Operating Cash Flow to Interest Expense	-50.68	-54,070.00	-22,144.00	-23,412.00	-20,704.00	0.00	0.00	0.00	-528.28	-892.83	-90.81
Operating Cash Flow Less CapEx to Interest Expense	-709.16	-65,894.00	-26,670.50	-27,921.00	-23,097.00	0.00	0.00	0.00	-597.31	-987.33	-119.79
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.24	0.25	0.24	0.26	0.28	0.32	0.36	0.41	0.45	0.49	0.54
Accounts Receivable Turnover	5.91	5.58	5.49	5.62	5.81	6.58	6.59	7.92	7.93	8.84	8.09
Inventory Turnover	3.36	2.87	3.16	3.64	4.35	4.47	4.87	5.42	6.40	6.73	7.23
Fixed Asset Turnover	2.22	2.06	1.91	1.76	1.81	1.94	2.07	2.39	2.67	2.91	3.18
Accounts Payable Turnover	6.82	5.64	8.90	8.71	9.10	11.47	16.35	18.67	22.91	21.83	23.51
Days Sales Outstanding (DSO)	61.72	65.38	66.53	64.93	62.81	55.50	55.36	46.10	46.05	41.27	45.11
Days Inventory Outstanding (DIO)	108.75	127.20	115.39	100.22	83.83	81.74	74.93	67.40	57.04	54.24	50.46
Days Payable Outstanding (DPO)	53.52	64.75	41.03	41.92	40.10	31.81	22.32	19.55	15.93	16.72	15.53
Cash Conversion Cycle (CCC)	116.95	127.83	140.89	123.23	106.53	105.43	107.97	93.94	87.15	78.80	80.04
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	284	308	316	300	287	279	267	202	196	185	183
Invested Capital Turnover	1.05	0.82	0.79	0.79	0.86	0.89	0.95	1.18	1.30	1.42	1.55
Increase / (Decrease) in Invested Capital	180	90	57	7.32	2.60	-29	-49	-99	-91	-94	-84
Enterprise Value (EV)	1,481	908	470	800	826	1,804	1,690	2,580	2,371	2,487	2,085
Market Capitalization	1,986	1,347	857	1,157	1,163	2,116	1,984	2,869	2,647	2,758	2,342
Book Value per Share	$14.01	$13.19	$12.38	$11.62	$10.86	$10.26	$9.69	$8.44	$8.07	$7.68	$7.38
Tangible Book Value per Share	$11.42	$10.64	$9.87	$9.12	$8.42	$7.84	$7.31	$6.71	$6.36	$6.00	$5.71
Total Capital	789	746	704	658	623	590	560	491	473	456	440
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-505	-439	-388	-357	-336	-311	-293	-289	-276	-271	-257
Capital Expenditures (CapEx)	16	12	9.05	4.51	2.39	1.51	0.60	0.97	2.00	2.27	4.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.85	19	30	16	15	14	11	-1.34	-0.63	4.84	6.32
Debt-free Net Working Capital (DFNWC)	506	458	417	373	351	325	304	288	276	276	263
Net Working Capital (NWC)	506	458	417	373	351	325	304	288	276	276	263
Net Nonoperating Expense (NNE)	11	11	16	15	11	10	11	23	9.42	7.34	10
Net Nonoperating Obligations (NNO)	-505	-439	-388	-357	-336	-311	-293	-289	-276	-271	-257
Total Depreciation and Amortization (D&A)	4.95	5.29	7.03	8.49	8.50	8.17	8.30	8.30	6.66	6.38	6.40
Debt-free, Cash-free Net Working Capital to Revenue	0.42%	8.95%	12.95%	6.61%	5.92%	5.28%	3.98%	-0.46%	-0.20%	1.46%	1.82%
Debt-free Net Working Capital to Revenue	248.48%	212.25%	183.09%	158.29%	143.17%	123.87%	109.69%	97.58%	88.11%	83.49%	75.78%
Net Working Capital to Revenue	248.48%	212.25%	183.09%	158.29%	143.17%	123.87%	109.69%	97.58%	88.11%	83.49%	75.78%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.92)	($0.74)	($1.04)	($1.01)	($0.81)	($0.75)	($0.79)	($1.47)	($0.59)	($0.53)	($0.66)
Adjusted Weighted Average Basic Shares Outstanding	53.89M	56.44M	56.78M	57.04M	56.89M	57.50M	57.78M	58.15M	58.02M	59.16M	59.65M
Adjusted Diluted Earnings per Share	($0.92)	($0.74)	($1.04)	($1.01)	($0.81)	($0.75)	($0.79)	($1.47)	($0.59)	($0.53)	($0.66)
Adjusted Weighted Average Diluted Shares Outstanding	53.89M	56.44M	56.78M	57.04M	56.89M	57.50M	57.78M	58.15M	58.02M	59.16M	59.65M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	56.57M	56.86M	57.15M	57.40M	57.67M	57.82M	58.23M	58.59M	59.36M	59.65M	59.92M
Normalized Net Operating Profit after Tax (NOPAT)	-40	-31	-43	-34	-35	-33	-34	-31	-25	-24	-29
Normalized NOPAT Margin	-69.47%	-57.59%	-71.69%	-52.83%	-52.40%	-45.99%	-45.45%	-37.80%	-29.78%	-27.34%	-31.35%
Pre Tax Income Margin	-88.69%	-76.96%	-97.18%	-89.07%	-69.41%	-59.98%	-59.95%	-104.81%	-41.02%	-35.50%	-42.19%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-2,293.28	-44,787.00	-30,971.00	-60,740.00	-50,357.00	0.00	0.00	0.00	-1,322.14	-1,446.38	-292.38
NOPAT to Interest Expense	-1,592.39	-31,241.00	-21,572.95	-42,546.70	-35,077.70	0.00	0.00	0.00	-870.00	-1,010.45	-203.44
EBIT Less CapEx to Interest Expense	-2,951.76	-56,611.00	-35,497.50	-65,249.00	-52,750.00	0.00	0.00	0.00	-1,391.17	-1,540.88	-321.36
NOPAT Less CapEx to Interest Expense	-2,250.87	-43,065.00	-26,099.45	-47,055.70	-37,470.70	0.00	0.00	0.00	-939.04	-1,104.95	-232.42
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-3.56%	-2.89%	-2.81%	-2.34%	-2.15%	-2.83%	-3.18%	-2.31%	-1.90%	-0.79%	-0.01%

Financials Breakdown Chart

Key Financial Trends

Twist Bioscience Corp (NASDAQ: TWST) has continued to display significant operational challenges over the last four years with recurring net losses each quarter. Here are the key financial highlights and trends based on recent quarterly data through Q2 2025:

Operating revenue has steadily increased from $54.2 million in Q1 2023 to $92.8 million in Q2 2025, indicating top-line growth and improving market demand.
Total gross profit rose from $24.8 million in Q1 2023 to $46.0 million in Q2 2025, showing some enhanced operational efficiency at the gross margin level.
Cash and equivalents remain strong, peaking at $316.7 million in Q1 2023 with $210.4 million still available by Q2 2025, indicating a robust liquidity position to support ongoing operations and investments.
Issuance of common equity has raised capital in multiple quarters, such as $7.7 million in Q2 2025 and $15 million debt issuance in Q1 2025, helping fund operations and development.
Research and development expense remains consistently high (~$23 million to $31 million per quarter), reflecting strong investment in innovation but adding pressure on profitability.
Selling, general, and administrative expenses have increased over time, reaching $63.7 million in Q2 2025, which may be linked to scaling efforts but weigh on operating margins.
Non-cash adjustments and depreciation add significant costs each quarter but also reflect investments in assets and amortization of intangibles.
Net losses persist across all quarters, with Q2 2025 loss reaching approximately $39.3 million, despite revenue growth, indicating ongoing difficulties in reaching profitability.
Operating expenses consistently exceed gross profit, leading to negative operating income and pressuring the company's bottom line.
Total liabilities have increased from $163.6 million in Q1 2023 to $155.5 million in Q2 2025, with significant current and non-current liabilities that could impact financial flexibility if not managed carefully.

Overall, Twist Bioscience shows promising top-line growth and maintains a healthy cash position, which are positives for funding its technology development and market expansion. However, persistent net losses, high operating costs, and increasing liabilities raise concerns about when the company will become profitable. Investors should watch for continued improvements in operating leverage and cost management in future quarters.

10/26/25 04:07 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Twist Bioscience's Financials

When does Twist Bioscience's financial year end?

According to the most recent income statement we have on file, Twist Bioscience's fiscal year ends in September. Their fiscal year 2024 ended on September 30, 2024.

How has Twist Bioscience's net income changed over the last 7 years?

Twist Bioscience's net income appears to be on an upward trend, with a most recent value of -$208.73 million in 2024, rising from -$59.31 million in 2017. The previous period was -$204.62 million in 2023. Check out Twist Bioscience's forecast to explore projected trends and price targets.

What is Twist Bioscience's operating income?

Twist Bioscience's total operating income in 2024 was -$220.83 million, based on the following breakdown:

Total Gross Profit: $133.35 million
Total Operating Expenses: $354.18 million

How has Twist Bioscience's revenue changed over the last 7 years?

Over the last 7 years, Twist Bioscience's total revenue changed from $10.77 million in 2017 to $312.97 million in 2024, a change of 2,806.8%.

How much debt does Twist Bioscience have?

Twist Bioscience's total liabilities were at $141.63 million at the end of 2024, a 7.4% decrease from 2023, and a 429.9% increase since 2018.

How much cash does Twist Bioscience have?

In the past 6 years, Twist Bioscience's cash and equivalents has ranged from $46.74 million in 2019 to $465.83 million in 2021, and is currently $226.32 million as of their latest financial filing in 2024.

How has Twist Bioscience's book value per share changed over the last 7 years?

Over the last 7 years, Twist Bioscience's book value per share changed from 0.00 in 2017 to 8.07 in 2024, a change of 806.8%.

Related Companies

This page (NASDAQ:TWST) was last updated on 10/26/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Twist Bioscience (TWST) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Twist Bioscience's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Twist Bioscience (TWST) Financials

Annual Income Statements for Twist Bioscience

Quarterly Income Statements for Twist Bioscience

Annual Cash Flow Statements for Twist Bioscience

Quarterly Cash Flow Statements for Twist Bioscience

Annual Balance Sheets for Twist Bioscience

Quarterly Balance Sheets for Twist Bioscience

Annual Metrics And Ratios for Twist Bioscience

Quarterly Metrics And Ratios for Twist Bioscience

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Twist Bioscience's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools